Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has been given an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company. Marinus Pharmaceuticals’ rating score has declined by 25% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokers have set a 1-year consensus price objective of $17.00 for the company and are predicting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given Marinus Pharmaceuticals an industry rank of 61 out of 265 based on the ratings given to its competitors.
MRNS has been the topic of several research analyst reports. Zacks Investment Research upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Thursday, October 29th. Oppenheimer dropped their price objective on Marinus Pharmaceuticals from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, October 30th. Jefferies Group initiated coverage on Marinus Pharmaceuticals in a research note on Tuesday, November 17th. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, RBC Capital initiated coverage on Marinus Pharmaceuticals in a research note on Thursday, December 17th. They issued an “outperform” rating and a $14.00 price objective on the stock.
Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 7.64 on Monday. The firm’s 50-day moving average price is $6.60 and its 200-day moving average price is $10.79. The company’s market cap is $109.51 million. Marinus Pharmaceuticals has a 1-year low of $4.52 and a 1-year high of $20.72.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.16. Equities research analysts forecast that Marinus Pharmaceuticals will post ($1.57) EPS for the current fiscal year.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Company’s indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Company’s oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com